What genetic health risks should German Shepherd owners and breeders know about?

A practical guide to German Shepherd genetic risks: hip and elbow dysplasia, degenerative myelopathy, EPI, hemophilia, GDV risk, screening tests and how to read OFA/PennHIP results.

Overview

Sources used for recommendations include the Orthopedic Foundation for Animals (OFA), PennHIP (University of Pennsylvania), Merck Veterinary Manual, American Veterinary Medical Association (AVMA), and peer-reviewed veterinary genetics literature.

Major inherited conditions in German Shepherds

Hip dysplasia (why GSDs are high-risk)

• What it is: Hip dysplasia is a developmental disorder of the hip joint where laxity and abnormal congruity lead to osteoarthritis (OA). It is polygenic (many genes) and strongly influenced by environment (growth rate, nutrition, exercise).
• Why GSDs are at risk: GSDs have historically shown higher rates of clinically significant hip dysplasia compared with many other breeds, likely due to breed conformation (large size, rapid growth) and inherited susceptibility.
• Frequency and impact: Population frequencies vary by dataset and country; breed-specific reports (OFA/PennHIP) historically show GSDs among breeds with higher proportions of dysplastic hips. Affected dogs may develop lameness, reduced activity, muscle atrophy, and a shortened working lifespan.
• Management: Weight control, controlled exercise, physical therapy, joint supplements (omega‑3 EPA/DHA, glucosamine—evidence varies), and pain control (NSAIDs) are standard. In moderate to severe cases, surgical options include juvenile pubic symphysiodesis (JPS, early), double/triple pelvic osteotomy (DPO/TPO, in young dogs with minimal OA), or total hip replacement (THR) in older dogs.

Elbow dysplasia

• What it is: A set of developmental lesions affecting the elbow (fragmented medial coronoid process, osteochondritis dissecans, ununited anconeal process). Like hips, elbow dysplasia is polygenic and influenced by growth rate.
• Relevance for GSDs: GSDs are among larger breeds with increased risk. Elbow OA can cause front-limb lameness, pain, and early retirement from working roles.
• Screening and management: Radiographic screening (OFA elbow evaluations) is recommended. Early surgical correction for certain lesions can be beneficial; conservative management includes weight control, rehabilitation, and analgesia.

Degenerative myelopathy (DM)

• Genetics and pathophysiology: DM is a progressive neurodegenerative disease affecting the spinal cord in older dogs. A mutation in the SOD1 gene (a single nucleotide variant) is strongly associated with DM in multiple breeds, including GSDs. The inheritance pattern is complex: dogs homozygous for the SOD1 mutation have higher risk, but penetrance is incomplete—not all genetically at-risk dogs develop clinical disease.
• Clinical course: Typically presents as progressive pelvic limb weakness and ataxia in middle-aged to older dogs, progressing to paralysis over months to years.
• Testing and interpretation: A commercially available DNA test for the SOD1 mutation identifies dogs as clear, carrier (heterozygote), or at-risk (homozygote). Because penetrance is incomplete, a positive (homozygous) test predicts increased risk but not certainty of disease.
• Management: There is no cure. Physical therapy, mobility aids, and supportive care improve quality of life. Breeders should avoid mating two at-risk (homozygous) dogs; carrier × clear matings can be used strategically to preserve genetic diversity while preventing affected puppies.

Exocrine pancreatic insufficiency (EPI) / juvenile pancreatic acinar atrophy (PAA)

• What EPI is: Failure of the pancreas to produce digestive enzymes → maldigestion, weight loss despite normal appetite, voluminous foul-smelling stools.
• Breed predisposition: GSDs are overrepresented among dogs with EPI in referral populations. In many cases in young dogs, the underlying cause is pancreatic acinar atrophy (PAA), which is believed to have a genetic basis (polygenic/immunologic), though a single definitive causative mutation has not been universally identified.
• Diagnosis: Serum trypsin-like immunoreactivity (TLI) is the standard diagnostic test—low TLI confirms EPI.
• Management: Lifelong oral pancreatic enzyme replacement, vitamin supplementation, and dietary management lead to good quality of life in most dogs.

Hemophilia and inherited coagulopathies

• Overview: Hemophilia A (factor VIII deficiency) is an X‑linked recessive condition and has been reported in GSDs—affected males bleed abnormally and may present with spontaneous hemorrhage, postoperative bleeding, or bleeding with trauma. Other inherited clotting factor disorders (e.g., von Willebrand disease, factor VII or IX deficiencies) are rare but possible.
• Testing: Coagulation screening (prothrombin time [PT], activated partial thromboplastin time [aPTT]) will identify abnormal clotting, and specific factor assays or molecular testing can confirm diagnosis. Carrier females for X‑linked disorders are usually clinically normal but can be identified by genetic testing or pedigree analysis.
• Management: Acute bleeding requires veterinary emergency care (blood products, factor replacement where available). Genetic testing and careful breeding decisions prevent producing affected males.

Bloat (gastric dilatation–volvulus, GDV) predisposition

• Risk profile: GDV risk correlates strongly with breed conformation—deep, narrow chests—and multiple breeds including GSDs have an elevated risk compared with small-breed dogs, though they are not the highest-risk group (Great Danes, Standard Poodles, Weimaraners rank higher). Lifetime risk figures vary by study; GDV carries high morbidity and mortality if not treated promptly.
• Genetic and management components: There is evidence for familial risk and heritability in some breeds. Contributing environmental factors include rapid eating, single large daily meals, aerophagia, and elevated feeding bowls.
• Prevention strategies: Consider feeding multiple small meals, avoiding exercise immediately before/after meals, using slow-feed bowls, and discussing prophylactic gastropexy with your veterinarian for at-risk working or show dogs.

Recommended health screening program for German Shepherds

• Hips:

• Elbows:

• DNA tests:

• Coagulation/factor testing:

• For puppies or clinical concerns (EPI): measure TLI when clinical signs (chronic weight loss, diarrhea) present; routine genetic test for PAA is not universally available.

• OFA evaluations (hip/elbow) (https://www.ofa.org)
• PennHIP (https://www.pennhip.org)
• DNA testing laboratories accredited for canine genetics (ask your veterinarian)

How to interpret OFA and PennHIP results (practical guide)

OFA hip and elbow evaluations

• Hip ratings: Final OFA reports classify hips as Excellent, Good, Fair, Borderline, Mild, Moderate, or Severe hip dysplasia based on hip-extended radiographs and radiographic signs of OA. Excellent/Good/Fair are generally considered acceptable for breeding in many programs; borderline or worse should be used cautiously.
• Elbow ratings: OFA gives a pass/fail with descriptive categories for dysplasia severity.
• Use in breeding: OFA ratings reflect current joint status (presence of OA) and are more directly tied to clinical disease. Because OFA final ratings require dogs to be 24 months or older, they are commonly used for breeding clearances.

PennHIP distraction index (DI)

• What DI measures: Radiographic measurement of passive hip laxity (0.0 = no laxity, 1.0 = complete luxation).
• Interpreting DI: Lower DI indicates less laxity and lower risk. Typical interpretation thresholds used by many breeders/vets:

• Percentile ranking: PennHIP provides how a dog compares to its breed (e.g., 25th percentile = better than 75% of same-breed dogs). Many breeders select dogs with DI in the lower percentiles for breeding.
• Advantages: PennHIP quantifies laxity and can be used from 16 weeks, making it useful for early selection against hip laxity. It is more predictive of future OA risk than a single hip-extended view in young dogs.

Putting OFA and PennHIP together

• Use both approaches when possible: PennHIP early (from 16 weeks) to measure laxity and guide early selection; OFA final rating at 24 months to confirm radiographic OA status. Avoid breeding two dogs with poor OFA ratings or high PennHIP DI values.
• Remember environment matters: Even dogs with genetic predisposition may reduce risk with proper growth management, nutrition, and exercise.

Practical breeding and ownership recommendations

• For breeders:

• For owners of young GSDs:

• For owners of affected dogs:

Key Takeaways

• German Shepherds have higher-than-average risk for hip and elbow dysplasia, DM, and EPI; hemophilia and GDV are less common but important to consider.
• Use PennHIP (from 16 weeks) for early objective hip laxity assessment and OFA final evaluations at 24 months to confirm radiographic OA status.
• DNA testing for the SOD1 mutation (DM) is widely available and should be part of responsible breeding decisions; interpret results with the understanding of incomplete penetrance.
• There is no single DNA test that fully predicts EPI; diagnosis is clinical and confirmed with serum TLI. Long-term enzyme replacement therapy is highly effective.
• Good breeding practices, open health testing, controlled growth and weight management, and early screening reduce the incidence and impact of genetic disease.

Practical resources and further reading

• Orthopedic Foundation for Animals (OFA): https://www.ofa.org
• PennHIP (University of Pennsylvania): https://www.pennhip.org
• Merck Veterinary Manual: https://www.merckvetmanual.com
• American Veterinary Medical Association (AVMA) breed resources: https://www.avma.org

References (selected)

• OFA — Canine Hip and Elbow Dysplasia resources. https://www.ofa.org
• PennHIP — University of Pennsylvania. https://www.pennhip.org
• Merck Veterinary Manual, sections on hip dysplasia, elbow dysplasia, EPI, GDV, and inherited coagulopathies. https://www.merckvetmanual.com
• Awano T, Johnson GS, Wade CM, et al. SOD1 mutation associated with canine degenerative myelopathy. (peer-reviewed genetics literature—see veterinary genetics journals).

Frequently Asked Questions